癌症患者的COVID-19:风险与预防措施
本文综述了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染所致COVID-19的临床表型,从无症状、轻症到可致命的严重急性呼吸窘迫综合征(ARDS)。文中指出,癌症患者(尤其是肺癌和血液恶性肿瘤)感染COVID-19后发生严重并发症和死亡的风险更高。部分癌症治疗如CAR-T细胞疗法可产生细胞因子风暴,而细胞因子风暴也是重症COVID-19的标志,因此接受CAR-T细胞治疗的患者若感染COVID-19风险更高,并可采用抗细胞因子方法治疗。
要点
- 癌症患者(尤其肺癌和血液恶性肿瘤)感染COVID-19后发生严重并发症和死亡的风险更高。
- COVID-19表型从无症状、轻症到严重急性呼吸窘迫综合征(ARDS),后者常导致死亡,尤其在有基础疾病者中。
- CAR-T细胞疗法可产生细胞因子风暴,而细胞因子风暴也是重症COVID-19的标志。
- 接受CAR-T细胞治疗的患者若感染COVID-19,风险更高,可采用抗细胞因子方法治疗。
适用人群与场景
- 癌症患者,尤其是肺癌和血液恶性肿瘤患者。
- 接受CAR-T细胞治疗的患者。
- 有基础疾病者感染COVID-19后易发展为严重ARDS并常导致死亡。
处置流程与药物剂量
- 接受CAR-T细胞治疗的患者若感染COVID-19,可采用抗细胞因子方法治疗。
红旗征与不能漏的情况
- 严重急性呼吸窘迫综合征(ARDS)常导致死亡,尤其在有基础疾病者中。
证据类型、等级与局限
- 综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对癌症患者(尤其肺癌和血液恶性肿瘤)感染COVID-19后发生严重并发症和死亡的风险更高保持警惕。
- 接受CAR-T细胞治疗的患者若感染COVID-19风险更高,可采用抗细胞因子方法治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「研究设计与关键结果」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19. Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches.
参考来源
- Razavi A, Hamblin MR, Rezaei N, et al. COVID-19 in patients with cancer: Risks and precautions. Am J Emerg Med. 2021. PMID: 33546958. doi:10.1016/j.ajem.2021.01.067
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。